title: How well do clinicians and patients agree on depression treatment  outcomes? Implications for personalized medicine.
abstract: OBJECTIVE
  In order to inform outcomes assessments in personalized medicine research, we evaluated the level of agreement between self-reported (SR) and clinician-rated (CR) measures of depression severity before and after treatment with an antidepressant medication.
  
  
  METHODS
  We pooled data from three trials (totaling 2075 patients) assessing the efficacy of antidepressant monotherapy in major depressive disorder. Differences between CR (17-item Hamilton Rating Scale for Depression [HAM-D17]) and SR (30-item Inventory of Depressive Symptomatology-Self-Rated) scale scores were used to determine concordance between CR-SR ratings. The effect of anxiety (HAMD17 anxiety-somatization subscale score ≥7) on SR-CR agreement was also assessed.
  
  
  RESULTS
  The CR-SR scale agreement was good for response (κ = 0.64) and moderate for remission (κ = 0.57). Patients who rated their depression as less severe than the clinician were significantly more likely to respond to treatment than over-reporters (odds ratio = 1.62; 95% confidence interval: 1.17-2.25). Although anxiety did not impact the level of agreement, among patients with SR-CR discordance, high anxiety was associated with over-reporting of depression severity.
  
  
  CONCLUSIONS
  The levels of disagreement for response and remission were too high for CR and SR scales to be considered interchangeable for research on patient-level outcomes. Anxiety does not meaningfully impact SR-CR agreement.
authors.forename: Boadie W
authors.initials: BW
authors.lastname: Dunlop
authors.forename: Bhrett
authors.initials: B
authors.lastname: McCabe
authors.forename: James M
authors.initials: JM
authors.lastname: Eudicone
authors.forename: John J
authors.initials: JJ
authors.lastname: Sheehan
authors.forename: Ross A
authors.initials: RA
authors.lastname: Baker
mesh_terms: D000328:Adult; D000928:Antidepressive Agents / Q000627:therapeutic use; D001007:Anxiety / Q000503:physiopathology; D000068180:Aripiprazole; D003865:Major Depressive Disorder / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology / Q000523:psychology*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use; D057285:Precision Medicine / Q000379:methods; D011379:Prognosis; D011569:Psychiatric Status Rating Scales; D015363:Quinolones / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D057566:Self Report; D016896:Treatment Outcome
chemical_list: D000928:Antidepressive Agents; D010879:Piperazines; D015363:Quinolones; D000068180:Aripiprazole